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Response to the current ebolavirus outbreak based on
traditional control measures has so far been
insufficient to prevent the virus from spreading
rapidly. This has led to urgent discussions on the use
of experimental therapies and vaccines untested in
humans and existing in limited quantities, raising
political, strategic, technical and ethical questions.est biosafety concern, restricting work on infectiousEbolavirus outbreaks and disease
The ongoing outbreak in West Africa of ebolavirus
hemorrhagic fever (EHF) [1], lately also referred to as
Ebola virus disease (EVD), has led to a surge in public
interest and concern regarding this virus, which was first
discovered in 1976 during simultaneous outbreaks in
Zaire (now the Democratic Republic of the Congo) and
Sudan [2]. Humans initially contract the virus either
through contact with the infected reservoir, which is
thought to be fruit bats, or by hunting and butchering of
infected wildlife, particularly great apes. Since their dis-
covery, ebolaviruses have caused frequent outbreaks al-
most exclusively in Central Africa. However, the recent
emergence of Zaire ebolavirus in West Africa, resulting
in what is the largest outbreak to date (Figure 1), with
4,390 cases and 2,226 deaths as of 7 September 2014,
shows that ebolaviruses are more widely distributed than
previously thought. While EHF is commonly associated
with high case fatality rates (up to 90% for Zaire
ebolavirus, approximately 50% for Sudan ebolavirus, and
approximately 35% for Bundibugyo ebolavirus), the
pathogenicity of Taï Forest ebolavirus, which was discov-
ered in the mid-1990s in Ivory Coast, is unknown be-
cause only a single case has been reported, and Reston
ebolavirus, which is found in the Philippines, is consi-
dered apathogenic for humans. Outbreaks are usually* Correspondence: feldmannh@niaid.nih.gov
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article, unless otherwise stated.driven by human-to-human transmission as a result of
direct contact with live or deceased patients and their
body fluids, mainly during patient management and care,
and participation in traditional local burial practices.
Basic hygiene measures and barrier nursing techniques
are usually sufficient to disrupt ebolavirus transmission
and spread in the community. Nevertheless, because of
its high case fatality rate and the absence of licensed vac-
cines or treatments, this virus is considered of the high-
virus to a few maximum containment laboratories
worldwide. Despite the restricted and highly regulated
handling of the pathogen, there have been considerable
scientific achievements over the past years; however,
many challenges remain in the public health sector in
relation to identifying and managing cases and interrupt-
ing virus spread.Detecting and containing outbreaks
The first major challenge lies in outbreak recognition, as
exemplified by the current EHF outbreak in West Africa,
which took almost three months to recognize and even
longer to appreciate as a major public health concern
[1]. Initial disease symptoms, which occur suddenly after
an incubation period of up to 21 days, are rather non-
specific and include fever, malaise, headaches, muscle
pain, nausea, vomiting and diarrhea [2,3]. More charac-
teristic symptoms, such as hemorrhagic manifestations
including vomiting of blood, nosebleed, bloody or tarry
stool, and bleeding from injection sites, as well as a char-
acteristic rash, appear later in the disease course, and are
only obvious in about half of all patients. Pathogenesis
involves a combination of immune suppression, vascular
dysfunction, coagulopathy, and the dysregulation of
cytokine responses similar to systemic inflammatory
response syndrome (SIRS), ultimately resulting in multi-
organ failure and death [2,4]. Importantly, similar symp-
toms, particularly in the initial stages of disease, can also
be seen in patients infected with malaria and typhoid
fever, as well as many other endemic infectious diseasesed Central Ltd. This is an Open Access article distributed under the terms of the
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Figure 1. Map of the West African ebolavirus outbreak as of 7 September 2014. Country and province borders according to the CIA World
Factbook are indicated as black or grey lines, respectively. Provinces with no new cases in the 21 days prior to 7th September 2014 (according to
the WHO situation report from 12th September 2014) are highlighted in yellow, provinces with new cases in the 21 days prior to 7th September
in orange, and provinces showing cases for the first time in the 7 days prior to 7th September are highlighted in red. Case numbers for each
country are indicated, with each square representing 10 cases. Only countries with extensive person to person transmission are shown; Senegal
and Nigeria are not shown. Inserts show a typical treatment and isolation facility set up as part of the international response to the outbreak,
with the top insert showing the ELWA III treatment and isolation site, the middle insert showing the inside of a treatment tent, and the bottom
insert showing a lab worker inactivating patient samples in a portable isolation chamber (pictures courtesy of Barry Fields (CDC Nairobi) and Dave
Safronetz (NIH)).
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countries the fear of importation is justified, as demon-
strated by past importations of ebolavirus into South
Africa and the closely related marburgvirus into the
USA and the Netherlands, although these remain rare
events. However, the likelihood of importations has in-
creased in association with the current outbreak in West
Africa, where four capital cities that have multiple inter-
national travel connections are now affected, and with the
evacuation of confirmed cases among foreign aid workers.
Nevertheless, it is very important to realize that in most
non-endemic countries ongoing person-to-person trans-
mission, as we currently see in West Africa, is extremely
unlikely, due to better access to professional health care,
higher standards of hospital hygiene, patient management
and diagnosis, safer burial practices, and the current high
level of awareness among health care providers. Past experi-
ence has shown that even when diagnosis was delayed,secondary infections have not occurred during the rare in-
cidences of imported infections, further indicating the crit-
ical importance of basic personal protection and hospital
hygiene as key measures to control ebolavirus transmission.
Once an EHF outbreak is confirmed, rapid diagnosis
based on quantitative real-time polymerase chain reac-
tion (qRT-PCR) methodology, as well as serology and
antigen detection, is available. However, given the
remote locations in which outbreaks usually occur, this
either involves time-consuming shipping of samples to
more centrally located reference laboratories, or dis-
patching of mobile laboratories directly into the outbreak
area [5]. The main strategy for outbreak management fo-
cuses on the reduction of secondary transmission by iso-
lating infected individuals, the implementation of safe
burial practices, contact tracing to disrupt infection
chains, and education of the local population regarding
risk reduction [6]. From a public health perspective, this
Hoenen and Feldmann BMC Biology 2014, 12:80 Page 3 of 6
http://www.biomedcentral.com/1741-7007/12/80strategy is paramount, and it has been successful in the
past in controlling ebolavirus outbreaks; but it has so far
had only limited effect on the current outbreak in West
Africa. In terms of the individual patient, at this time, care
is limited to supportive treatment to maintain vital func-
tion. The importance of providing the best possible care
to patients is not only in helping to reduce case fatality
rates, but also because it increases compliance with isola-
tion procedures and, therefore, contributes to overall out-
break control.
To address the need for more rapid recognition of fu-
ture EHF outbreaks, awareness among the medical com-
munity about EHF needs to remain high between
outbreaks. Once cases are identified, a multidisciplinary
approach, including the open and timely sharing of all
relevant information, is imperative for a successful out-
break response.
Developing and deploying countermeasures
Currently no licensed vaccines or therapeutics are avail-
able for ebolaviruses. Over the past decade, however,
funding has been made available for research into such
countermeasures, resulting in encouraging progress on
the preclinical level (Figure 2) [7]. Further, reverse genet-
ics technologies have generated non-infectious systemsFigure 2. Promising countermeasures against ebolaviruses. Listed are
judgment), all of which show 100% protection in non-human primates (NH
the case of vaccines, only those that require a single vaccination are shownthat allow modeling of the complete ebolavirus life cycle
without the need for maximum containment laborator-
ies. Together with reporter-expressing recombinant ebo-
laviruses, these systems have significantly improved our
ability to identify new antivirals [8]. The most promising
antivirals at this point include the combinations of three
monoclonal antibodies, which were protective in non-
human primates (the most stringent disease model) up
to two days after challenge, and when used in combin-
ation with interferon alpha were even protective if treat-
ment was initiated three days after challenge, that is,
after the onset of symptoms [9,10]. This approach is
now further being developed as ZMapp, an improved
antibody cocktail that is able to protect non-human pri-
mates with treatment starting as late as five days after
challenge [11], and was recently administered to a small
number of infected aid workers. Another very promising
approach is the use of small interfering RNAs (siRNAs),
which was also protective in non-human primates if
given after exposure [12]. This approach is currently be-
ing developed as a commercial drug called TKM-Ebola,
and while a phase I clinical trial was put on hold by the
FDA in July 2014, on 7 August 2014 this ban was par-
tially lifted, enabling the potential use of this drug in
EHF patients.the most advanced countermeasures (based on the authors’
Ps). Vaccines are shown in blue and antivirals are shown in green. In
.
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several platforms being highly protective in nonhuman
primate models [13]. The furthest developed of these
vaccines are based on viral vectors, since earlier attempts
using inactivated vaccines were unsuccessful, and live-
attenuated vaccines are generally considered too danger-
ous in the case of ebolaviruses. Viral vector-based
vaccines are recombinant vaccines in which genes en-
coding proteins of a pathogenic virus such as ebolavirus
are inserted into the genome of another virus that causes
mild or no disease. The viruses mostly used in ebolavirus
vaccines are either recombinant, replication-deficient ad-
enoviruses (Ads) or attenuated vesicular stomatitis vi-
ruses (VSVs), both of which are not known to cause
serious side effects in humans. The ebolavirus genes en-
code proteins that can be recognized by the immune
system but do not cause disease. The adenovirus plat-
form uses a non-replicating recombinant adenovirus car-
rying the genetic information for the ebolavirus surface
glycoprotein (GP) or for both GP and the ebolavirus nu-
cleoprotein. Vaccination with this virus leads to the pro-
duction of these proteins in the vaccinated individual,
resulting in the development of an adaptive immune re-
sponse. Most studies were performed using the human
Ad5 serotype, with which many people have been in-
fected at some point in their life. While in non-human
primate studies this vaccine confers complete protection
if given four weeks prior to challenge, in humans there
are significant problems with preexisting immunity
against the Ad5 serotype, so that individuals who have
been previously exposed to Ad5 fail to mount an im-
mune response to the ebolavirus component of the vac-
cine. While the Ad5-based vaccine was safe and
immunogenic in a phase I clinical trial, the immune re-
sponse was likely insufficient to confer protection [14].
The problem of preexisting immunity has been ad-
dressed by using different serotypes, including the rare
human serotypes Ad26 and Ad35, chimpanzee Ad3,
Ad7, and Ad63, as well as simian Ad21. Limited studies
showed 100% protective efficacy in non-human primates
after a single vaccination for the chimpanzee Ad3-based
vaccine, although a booster immunization was required
to achieve long-lasting immunity [15]. A phase I clinical
trial with this vaccine began in early September 2014.
The VSV platform uses an attenuated replication-
competent recombinant VSV that contains the ebola-
virus GP gene instead of its own glycoprotein gene,
leading to the production of virus particles that incorp-
orate the ebolavirus glycoprotein into the virus enve-
lope, as well as the production of this protein in
vaccinated individuals. In extensive studies this virus has
been shown to protect 100% of non-human primates if
given either three or four weeks prior to challenge [16],
and surprisingly it also showed some potential in post-exposure use, with 50 to 100% survival of non-human pri-
mates if the vaccine was administered 20 to 30 minutes
after challenge, depending on the species of the challenge
ebolavirus. This vaccine platform has not progressed into
clinical trials yet, but it was shown to be safe in severely
immunocompromised non-human primates, and also did
not cause neural pathology even after intrathalamic ad-
ministration to non-human primates [17,18]. This is im-
portant because although VSV is non-pathogenic in
humans, it can be neurovirulent in mice, and the
possibility of neural pathology in humans must be ruled
out - especially since, in contrast to the adenovirus-based
vaccine, the VSV-based vaccine remains replication-
competent. There has been a single use of this vaccine as
a potential post-exposure treatment after a needle-stick in-
cident in a laboratory worker in Hamburg, Germany, with
no side effects other than a transient fever [19]. A first
phase I clinical trial is planned for fall 2014.
One pressing and extremely difficult question is whether
such experimental treatments and vaccines should be used
in the current outbreak. The recent WHO declaration to
ethically approve the use of experimental drugs and vac-
cines under certain circumstances is likely to improve
current outbreak response strategies. However, one needs
to remain realistic regarding what can be done during the
current outbreak, given both the extremely limited
amount of clinical grade material that is available and the
lack of human safety data for any of the promising experi-
mental drugs and vaccines. Clearly, improving the chances
of survival of an infected patient is highly desirable. Im-
proved survival might also help to change a perception in
the population that the isolation wards are ‘death traps’ ra-
ther than medical care facilities, which could lead in turn
to improved compliance with conventional outbreak con-
trol measures. However, because of the general lack of hu-
man safety and efficacy data for these experimental drugs
and vaccines there is a risk of adverse effects and/or inef-
fectiveness, which could result in the perception that de-
veloped countries are experimenting on African patients.
The consequent deterioration in the relationship between
the affected African population and foreign health care
workers might decrease compliance with outbreak control
measures and may even lead to aggression, ultimately
resulting in further or even complete loss of outbreak con-
trol. This risk scenario applies in particular to the more re-
cent demands for the testing of certain drugs approved/
licensed for other medical applications, which counteract
human host responses that have been implied in the
pathogenesis of EHF, but without preclinical efficacy data
for those drugs against EHF. Safety of a drug targeting a
host response mechanism predicted to be relevant during
ebolavirus infection seems too weak as a justification con-
sidering the potentially disastrous consequences of a fail-
ure in efficacy on the ground.
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designed strategy, and this is particularly the case when
supplies are limited, as they are at the moment. In
addition, different situations may call for the use of dif-
ferent countermeasures. For example, foreign health care
workers may be best served by using a safe and effective
vaccine approach, whereas confirmed patients will need
a therapeutic approach such as an antiviral (for example
ZMapp or TKM-Ebola). Local health care staff and fam-
ily members may benefit from a ring vaccination ap-
proach (that is, vaccination of actual or potential
contacts to infected individuals) using a fast-acting vac-
cine such as the recombinant VSV, or prophylactic treat-
ment using an antiviral or therapeutic. If experimental
countermeasures are used, clinical safety and efficacy
data should certainly be collected whenever possible.
The question, however, is how that can be integrated
with currently ongoing outbreak control measures, and
whether we can ethically justify control groups if the
countermeasures have high prediction values for success.
In addition, giving some patients and health care or aid
workers priority for treatment or vaccination will cer-
tainly create discord among the affected population, aid
organizations, and governments, as decisions are un-
likely to be seen as politically, ethnically and ethically
correct by all parties. Regardless, targeting of health care
workers with vaccination might be one justified instance
for the following reasons: first, they are at significant risk
for acquiring EFH as an inherent part of their work;
second, they are absolutely essential to the on-going
management of the outbreak, and thus for public
health; and third, they might be in a better position to
give informed consent to receive an experimental
countermeasure. Despite all of the complications, we
should not forget that using countermeasures could
have a tremendous positive impact on the current out-
break, and provide us with a great chance to gain expe-
riences that can then be applied during the inevitable
future outbreaks.
The decisions regarding whether to deploy experimen-
tal countermeasures, which countermeasure to deploy,
and how to do so are extremely complex and difficult, and
will have to involve a careful risk/benefit evaluation, not
only on the level of an individual patient, but also for over-
all outbreak management. These decisions should be
made jointly with all affected parties, including scientists
and public health experts, the aid organizations involved
in outbreak management, and most importantly represen-
tatives of the people directly affected by the outbreak. As a
note of caution, any use of countermeasures should not
affect strengthening the traditional public health response
measures, which have a very successful track record and
are likely to be successful in this outbreak if widely and
rigorously applied.Future directions
Research has made significant progress in combating
ebolavirus infections. We now have to translate these
scientific advances into tangible benefits for the people
affected by this devastating disease. Events in the current
outbreak are rapidly developing, and it is impossible for
the authors to predict what measures will have been
taken by the time this article is published. However, re-
gardless of whether experimental countermeasures are
eventually used in the current ebolavirus outbreak, it is
clear that their use can only be considered a last resort
and that the strengthening of traditional public health
and outbreak response measures are of paramount im-
portance. For the future, the major challenge lies in ad-
vancing the experimental treatments and vaccines
towards licensing for human use. Further, deployment
strategies have to be put into place both for delivering
countermeasures into an outbreak area, and for their ad-
ministration. It will also be necessary to consider the
possibility that infections will be imported into countries
in which infections with ebolaviruses do not normally
occur, and to develop management plans. Again, over-
coming this challenge will require collaboration between
scientists, aid organizations, pharmaceutical companies,
local communities, regulatory bodies, and governments.
Noteworthy is the currently increasing interest in indus-
try as well as in politics in ebolaviruses, something that
has to be seen as a positive development [20]. Finally, fu-
ture efforts should not be restricted to ebolaviruses, but
also include other communicable pathogens with the po-
tential to cause devastating outbreaks, such as the
closely related marburgviruses. Even once the current
EHF outbreak in West Africa ceases, it is only a matter
of time until the next outbreak strikes. One should
wisely use this opportunity to be proactive.
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